Syndax Pharmaceuticals (SNDX) Institutional Ownership

During the previous two years, 193 institutional investors and hedge funds held shares of Syndax Pharmaceuticals. The most heavily invested institutionals were Kynam Capital Management LP ($122.31M), State Street Corp ($72.59M), Vanguard Group Inc. ($64.54M), Wellington Management Group LLP ($55.98M), Point72 Asset Management L.P. ($53.48M), Sofinnova Investments Inc. ($44.22M), and BVF Inc. IL ($40.52M).Learn more on SNDX's institutional investors.

Of the 157 institutional investors that purchased Syndax Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: BVF Inc. IL ($2.57M), Assenagon Asset Management S.A. ($2.26M), Kynam Capital Management LP ($1.72M), Avoro Capital Advisors LLC ($1.67M), Franklin Resources Inc. ($1.56M), Soleus Capital Management L.P. ($1.40M), and Vanguard Group Inc. ($1.34M).

Institutional investors have bought a total of 34,142,173 shares in the last 24 months. This purchase volume represents approximately $636.71M in transactions.

Of the 90 institutional investors that sold Syndax Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Wellington Management Group LLP ($4.89M), Eversept Partners LP ($3.76M), Jennison Associates LLC ($2.47M), PFM Health Sciences LP ($2.12M), Avoro Capital Advisors LLC ($1.95M), Barclays PLC ($1.63M), and Marshall Wace LLP ($1.18M).

Institutional investors have sold a total of 26,109,448 shares in the last 24 months. This volume of shares sold represents approximately $443.56M in transactions.